MINK THERAPEUTICS
MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
MINK THERAPEUTICS
Industry:
Biopharma Biotechnology Manufacturing
Founded:
2017-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.minktherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
212.994.8250
Email Addresses:
[email protected]
Technology used in webpage:
SPF Euro Google Google Cloud Google Cloud Iowa Zoom Video Conferencing Zoom DNS Made Easy DNS Dropbox Business
Current Employees Featured
Stock Details
Official Site Inspections
http://www.minktherapeutics.com Semrush global rank: 2.29 M Semrush visits lastest month: 8.25 K
- Host name: 197.48.209.35.bc.googleusercontent.com
- IP address: 35.209.48.197
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "MiNK Therapeutics"
Contact - MiNK Therapeutics
315 Cambridge Science Park Milton Road Cambridge. CB4 OWG United KingdomSee details»
MiNK Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 212.994.8250 MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, …See details»
MiNK Therapeutics - LinkedIn
MiNK Therapeutics | 5,267 followers on LinkedIn. Changing lives through living medicines. | We are a clinical stage biopharmaceutical company pioneering the discovery, development, and ...See details»
MiNK Therapeutics, Inc. (INKT) Company Profile & Overview
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T …See details»
Careers - MiNK Therapeutics
At MiNK Therapeutics, we’re passionate about developing novel cell therapies using our iNKT technology platform to improve the lives of patients worldwide. We have created a collaborative and inclusive environment that thrives on …See details»
MiNK Therapeutics' AgenT-797 Shows Promising Results in the …
Feb 6, 2024 Treatment with agenT-797 Showed Improved Survival in Severe Respiratory DistressNEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. …See details»
MiNK Therapeutics Corporate Update and First Quarter 2022 …
May 10, 2022 Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA …See details»
MiNK Therapeutics to Report Second Quarter 2022 Financial …
Jul 27, 2022 Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET. NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical …See details»
MiNK Therapeutics Announces Promising Preclinical Activity of …
Apr 8, 2024 MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including …See details»
Manufacturing - MiNK Therapeutics
MiNK Therapeutics, Inc. 149 Fifth Avenue Suite 500 New York, NY 10010. Phone: 212.994.8250. Email: [email protected]See details»
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate …
Dec 20, 2023 MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic …See details»
MiNK Therapeutics Announces Promising Preclinical Activity of …
Apr 8, 2024 MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including …See details»
MiNK Therapeutics, Inc. (INKT) - Yahoo Finance Canada
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T …See details»
MiNK Therapeutics Announces Patients Dosed with AgenT-797 …
Mar 3, 2022 Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity Clinical trials …See details»
Cancer - MiNK Therapeutics
Invariant natural killer T (iNKT) cell therapies leverage both adaptive and innate immune systems. Our investigational allogeneic iNKT cell therapy candidates directly attack tumor cells via TCR …See details»
MiNK Therapeutics, Inc. (INKT) - Stock Analysis
5 days ago Website https://minktherapeutics.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 2 analysts, the average rating for INKT …See details»
MiNK Therapeutics Announces $5.8 Million Private Placement and ...
May 13, 2024 Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor …See details»
Mink Therapeutics Inc (INKT) Stock Price & News - Google
Get the latest Mink Therapeutics Inc (INKT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
MiNK Therapeutics to Report Third Quarter 2022 Financial Results …
Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET. NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company …See details»